Aktuellt
SENASTE
Redeye comments on Nanexa’s Q2 2023 report and endorses the company’s recent progress related to NEX-20 and NEX-22. Once the company’s coming financing need is sorted, and the positive progress of NEX-20 and NEX-22 continues, we see the potential for a positive share momentum in the coming 12–18 months. Given the initial pharmacokinetic data from the clinical phase I trial with NEX-20, we nudge our base case to SEK6.4 (6.1).
LÄS MER
